TBPH Theravance Biopharma Inc.

-0.01  -0%
Previous Close 21.27
Open 21.3
Price To Book -8.79
Market Cap 1,204,103,428
Shares 56,637,038
Volume 123,727
Short Ratio
Av. Daily Volume 297,779

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released September 20, 2017 - primary endpoint met.
Closed Triple - IMPACT
Approved June 21, 2013.
VIBATIV (telavancin hydrochloride) for injection
Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)
Approved April 30, 2015.
Phase 3 data due 2H 2020.
Ampreloxetine (TD-9855)
Phase 3 data released May 2, 2019 met primary but missed key secondary endpoint.
Closed Triple - CAPTAIN
Approval announced September 19, 2017.
Closed Triple
FDA Approval announced November 9, 2018.
Phase 2b data released August 2, 2017. Primary endpoint not met.
Velusetrag (TD-5108)
Phase 2 data released June 2016
Hepatitis C virus (HCV)
Phase 3 trial discontinued following recent interim analysis.
Phase 3 first patient enrolled late February 2015. Data due 2017
Staphylococcus aureus bacteremia
Phase 3 data due in 2016
Chronic obstructive pulmonary disease (COPD
Phase 2 data due late-2020.
Crohn's Disease
Phase 2b data due late-2020.
Ulcerative Colitis
Phase 1 data due September 2019.

Latest News

  1. Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises
  2. How Theravance Biopharma, Inc. (NASDAQ:TBPH) Can Impact Your Portfolio Volatility
  3. Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil
  4. Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat
  5. Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates
  6. Corcept's (CORT) Earnings & Revenues Miss Estimates in Q2
  7. Edited Transcript of TBPH earnings conference call or presentation 31-Jul-19 12:00pm GMT
  8. Theravance (TBPH) Q2 Loss Narrower, Revenues Beat Estimates
  9. Theravance Biopharma, Inc. (TBPH) Q2 2019 Earnings Call Transcript
  10. Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates
  11. Theravance Biopharma, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update
  12. Theravance Biopharma Reports New Data from Phase 2 Study of Ampreloxetine (TD-9855) in Oral Presentation at 32nd European Neurology Congress
  13. New antibiotics desperately needed for rising tide of drug-resistant ‘superbugs’
  14. How Much Did Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Pocket Last Year?
  15. Drug maker stocks rally after AbbVie's deal to buy Allergan for 45% premium
  16. AstraZeneca's Triple-Combo COPD Inhaler Gets Japan's Nod
  17. See what the IHS Markit Score report has to say about Theravance Biopharma Inc.
  18. Introducing Theravance Biopharma (NASDAQ:TBPH), The Stock That Slid 54% In The Last Five Years
  19. The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs